Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as firstline treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.

Saved in:

Bibliographic Details
Title:	Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as firstline treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.
Authors:	Akihiko Ueda¹ aueda@kuhp.kyoto-u.ac.jp, Hidemichi Watari², Masaki Mandai¹, Shunichi Fukuhara^3,4, Yasuo Sugitani⁵, Kiyoko Ogino⁶, Shuichi Kamijima⁶, Takayuki Enomoto⁷
Source:	Journal of Gynecologic Oncology. Nov2022, Vol. 33 Issue 6, p1-14. 14p.
Database:	Academic Search Ultimate

Description
ISSN:	20050380
DOI:	10.3802/jgo.2022.33.e78